HomeCUP • FRA
add
Chugai Pharmaceutical Co Ltd
Previous close
€30.32
Day range
€28.48 - €28.60
Year range
€22.60 - €39.80
Market cap
8.06T JPY
Avg Volume
148.00
P/E ratio
-
Dividend yield
-
Primary exchange
TYO
In the news
Financials
Income Statement
Revenue
Net income
| (JPY) | Dec 2023info | Y/Y change |
|---|---|---|
Revenue | 273.81B | -37.56% |
Operating expense | 60.18B | -20.94% |
Net income | 91.21B | -11.00% |
Net profit margin | 33.31 | 42.53% |
Earnings per share | — | — |
EBITDA | 129.51B | -17.68% |
Effective tax rate | 25.66% | — |
Balance Sheet
Total assets
Total liabilities
| (JPY) | Dec 2023info | Y/Y change |
|---|---|---|
Cash and short-term investments | 738.98B | 46.88% |
Total assets | 1.93T | 3.36% |
Total liabilities | 306.97B | -31.08% |
Total equity | 1.63T | — |
Shares outstanding | 1.65B | — |
Price to book | 0.03 | — |
Return on assets | 16.21% | — |
Return on capital | 19.15% | — |
Cash Flow
Net change in cash
| (JPY) | Dec 2023info | Y/Y change |
|---|---|---|
Net income | 91.21B | -11.00% |
Cash from operations | 124.21B | 559.99% |
Cash from investing | 5.64B | 125.64% |
Cash from financing | -2.30B | 2.34% |
Net change in cash | 127.33B | 345.46% |
Free cash flow | 117.39B | 452.44% |
About
Chugai Pharmaceutical Co., Ltd. is a drug manufacturer operating in Japan. It is a subsidiary controlled by Hoffmann-La Roche, which owns 62% of the company as of 30 June 2014. The company is headquartered in Tokyo. Osamu Nagayama is the current representative director and chairman. Tatsuro Kosaka is the current representative director, president and CEO. Wikipedia
CEO
Founded
Mar 10, 1925
Website
Employees
7,604
